Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Ovarian Cancer
  •  Kidney Cancer
  •  Haemato-Oncology
  •  Colon Cancer
  •  Melanoma/Skin Cancer
  •  Hormone Therapy
  •  Neoadjuvant Therapy
  •  Cervical Cancer

Abstract

Citation: Clin Oncol. 2016;1(1):1063.DOI: 10.25107/2474-1663.1063

Prognostic Factors for Ependymoma Survival: A Retrospective Study

Nizamutdinov D, Dandashi JA, Stock EM, Kirmani BF, Stroberg E, Wu E, Dayawansa S, Huang JH and Fonkem E


Department of Neurosurgery, Baylor Scott & White Health, USA
College of Medicine, Texas A&M Health Science Center, USA
Department of Pathology, Baylor Scott & White Health, USA
Cooperative Studies Program Coordinating Center (CSPCC), VA Maryland Health Care System, USA
Department of Neurology, Baylor Scott & White Health, USA These authors contributed equally to this work

*Correspondance to: Ekokobe Fonkem 

 PDF  Full Text Research Article | Open Access

Abstract:

Background: Ependymoma is a rare primary brain tumor that arises from the ependymal cells of the intra-ventricular central nervous system.
Methods: Thirty-two clinical cases of ependymoma were obtained from the tumor registry of the Scott & White Integrated Healthcare System from 1976 to 2013. We investigated the effects of gender, age, race, tumor grade, surgical method, recurrence, radiation therapy (RT), chemotherapy (CT), and mortality of patients.
Results: Fifty percent of patients had RT and 12.5% had CT. Tumor recurrence was observed in only 4 (12.5%) cases and all were diagnosed with grade II tumors. Sixteen patients (50.0%) underwent subtotal resection, 11 (34.4%) gross total, and 5 (15.6%) underwent no surgical procedures. Twentytwo patients (68.8%) are still living and 10 (31.3%) were deceased at time of analysis. Forty percent of deceased were under 18 year of age. The median overall survival time for all patients was 15.2 years (182.5 months), with a 5-year survival rate of 80.0%. Patients with primary tumor sites in the brain stem, frontal, and parietal lobes had survival rates of 87.5%, 100%, and 100%, respectively, with no reported tumor recurrence (0.0% each).
Conclusion: Surgical treatment with attempted gross total resection was the most successful method of ependymoma treatment. Primary tumor site is another important prognostic value for evaluation of short and long-term outcomes of ependymoma diagnosed patients. Impact: This study aims to identify novel prognostic factors for survival and to describe effective treatments and outcomes of ependymoma diagnosed patients.

Keywords:

Ependymoma; Prognostic factors; Survival; Outcomes; Epidemiology

Cite the Article:

Nizamutdinov D, Dandashi JA, Stock EM, Kirmani BF, Stroberg E, Wu E, et al. Prognostic Factors for Ependymoma Survival: A Retrospective Study. Clin Oncol. 2016; 1: 1063.

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Genomic-wide Copy Number Variation Profile and a New IKZF1 Gene Variation in Chinese Adult Acute Lymphoblastic Leukemia
 Abstract  PDF  Full Text
Identification of Ethylenediurea and Benzyl (Phenoxy) Acetic Acid Derivatives, a Potential Cocktail Therapy for Ischemia
 Abstract  PDF  Full Text
View More...